

1 Estimating changes in antibiotic consumption with the introduction 2 of doxycycline post-exposure prophylaxis in the United States

3
4 Kirstin I. Oliveira Roster¹ and Yonatan H. Grad*¹

5
6 ¹. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
7 Health, Boston MA

8 * Correspondence: ygrad@hsph.harvard.edu
9

10 11 **Abstract**

12 Doxycycline as post-exposure prophylaxis (doxy-PEP) reduces the risk of gonorrhea,
13 chlamydia, and syphilis in studies of men who have sex with men (MSM) and
14 transgender women (TGW) on HIV Pre-exposure Prophylaxis (PrEP) and people living
15 with HIV (PLWH). Doxy-PEP is an important tool to address the increasing burden of
16 sexually transmitted infections (STIs), but there is concern that increased consumption
17 of doxycycline may drive antimicrobial resistance. We estimated the expected increase
18 in antibiotic use in the US under several doxy-PEP prescribing scenarios. We
19 accounted for doses of antibiotics that may be averted due to the prevention of
20 chlamydia, gonorrhea, and syphilis infections by doxy-PEP. Under a scenario of 75%
21 adoption among the eligible population, with rates of consumption similar to the
22 DoxyPEP trial population, monthly antibiotic consumption would increase by around
23 2.52 million doses, driven by doxy-PEP consumption of 2.58 million doses and less 62.1
24 thousand antibiotic doses that would otherwise have been used for chlamydia,
25 gonorrhea, and syphilis treatment.
26
27

28 Doxycycline as post-exposure prophylaxis (doxy-PEP), a 200mg dose of doxycycline
29 taken within 72 hours of condomless sex, reduces the risk of gonorrhea, chlamydia, and
30 syphilis in studies of men who have sex with men (MSM) and transgender women
31 (TGW) on HIV Pre-exposure Prophylaxis (PrEP) and people living with HIV (PLWH))
32 (1,2) . Local and state departments of public health have published clinical guidelines
33 for prescribing doxy-PEP (e.g., (3,4)) and national guidelines are expected soon.

34
35 Doxy-PEP is an important tool to address the increasing burden of sexually transmitted
36 infections (STIs), but there is concern that increased consumption of doxycycline may
37 drive antimicrobial resistance, including doxycycline resistant *N. gonorrhoeae*,
38 *Staphylococcus aureus*, and *Streptococcus pneumoniae* (5–8).

39
40 How may antibiotic consumption change with the adoption of doxy-PEP? Addressing
41 this question may inform considerations of the risks of antimicrobial resistance and the
42 benefits of STI prevention. Here, we estimated the expected increase in antibiotic
43 consumption in the US under several doxy-PEP prescribing scenarios. We accounted
44 for defined daily doses (DDDs), hereafter simply referred to as *doses*, of antibiotics that
45 may be averted due to the prevention of chlamydia (doxycycline), gonorrhea
46 (ceftriaxone), and syphilis (penicillin) infections by doxy-PEP, with relative risk estimates
47 as reported in the US trial (1) (**Supplemental Table S1**).

48
49 We estimated that 0.86 million MSM may be eligible for a doxy-PEP prescription under
50 the enrollment criteria of the DoxyPEP trial (1) (0.53 million PLWH and 0.33 million HIV
51 PrEP users; **Supplemental Table S1**). Under a scenario of 75% adoption among this
52 population (**Supplement**), with rates of consumption similar to the DoxyPEP trial
53 population (4 doses per person-month)(1), monthly antibiotic consumption would
54 increase by around 2.52 million doses, driven by doxy-PEP consumption of 2.58 million
55 doses and less 62.1 thousand antibiotic doses that would otherwise have been used for
56 chlamydia, gonorrhea, and syphilis treatment (**Supplemental Table S2**). Under a
57 scenario of widespread prescribing of doxy-PEP to the entire eligible population (100%
58 adoption), monthly antibiotic consumption would be expected to increase by 3.36 million
59 doses (**Supplemental Table S4**).

60 A study of ten prescribing strategies based on a patient's PrEP use, HIV status, and
61 bacterial STI history projected substantial variation across the strategies in the number
62 of infections averted per person taking doxy-PEP (9). The prescribing criterion with the
63 lowest number needed to treat to prevent a chlamydia infection was a diagnosis of two
64 bacterial STIs within six months. Adoption of this strategy with 75% uptake among MSM
65 on HIV PrEP and PLWH would lead to an increase in monthly antibiotic consumption of
66 0.28 million doses, while widespread (100%) adoption would lead to an increase of 0.37
67 million doses (**Supplemental Table S5**). Among bacterial STI history-based prescribing
68 strategies, the increase in antibiotic consumption was directly related to the size of the
69 treated population (9); prescribing doxy-PEP to individuals with a diagnosis of at least
70 two concurrent bacterial STIs would be expected to result in the smallest population
71 treated and also the smallest increase in antibiotic consumption (0.18 and 0.24 million
72 doses per month with 75% and 100% adoption, respectively; **Supplement, Equations**
73 **2.1-2.3, Table S5**).

74

75 A net zero change in doxycycline consumption, where doxy-PEP consumption is
76 balanced with the number of averted doxycycline doses for chlamydia treatment, would
77 require restricting prescriptions to a group with incidence of 7.8 infections per person-
78 year, while maintaining similar levels of monthly doxy-PEP consumption and reductions
79 in chlamydia infection risk reported for HIV PrEP users (**Supplement, Equations 3.1-**
80 **3.3**).

81

82 Our estimates were based on first-order, short-term use of doxy-PEP. We did not
83 consider the indirect protective effects of doxy-PEP among non-users, which at least
84 initially are expected to reduce bacterial STI incidence (10). We relied on the average
85 estimates of doxy-PEP consumption and relative risk of infection reported in the
86 DoxyPEP trial (1) for all strategies, though these measures likely vary depending on the
87 population treated. Our estimates of antibiotic doses avoided by doxy-PEP considered
88 treatment for uncomplicated chlamydia and gonorrhea and primary syphilis and not for
89 disseminated gonorrhea or for secondary or tertiary disease. Future research is needed
90 to understand consumption and risk among more granular groups and to identify
91 strategies that minimize the number of antibiotic doses consumed (not only the number
92 needed to treat) while preventing the greatest number of STIs.

93

94 These estimates suggest that doxycycline consumption is expected to increase with the
95 introduction of doxy-PEP, even when accounting for the reduction in antibiotics used to
96 treat chlamydia, gonorrhea, and syphilis, though the extent of the increase will depend
97 on the size of the population that uses doxy-PEP. Monitoring the changes in the extent
98 of antibiotic consumption, along with changes in disease incidence and the burden of
99 resistance, will be important to understand doxy-PEP's impact.

100

101 Funding Statement: This work was supported by National Institute of Allergy and
102 Infectious Diseases (grant numbers R01 AI132606 and R01 AI153521) and CDC
103 contract number 200-2016-91779 to Y. H. G. The findings, conclusions, and views
104 expressed are those of the authors and do not necessarily represent the official position
105 of the Centers for Disease Control and Prevention (CDC).

106 **References**

- 107
- 108 1. Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al.
109 Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. *N Engl J*
110 *Med.* 2023;388(14):1296–306.
- 111 2. Molina JM, Bercot, Beatrice, Assoumou L, Michele, Algarte-Genin, Rubenstein, Emma,
112 Pialoux, Gilles, et al. ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO
113 PREVENT STIs IN MSM ON PrEP - CROI Conference. In 2023 [cited 2023 Sep 8]. Available
114 from: [https://www.croiconference.org/abstract/anrs-174-doxyvac-an-open-label-randomized-](https://www.croiconference.org/abstract/anrs-174-doxyvac-an-open-label-randomized-trial-to-prevent-stis-in-msm-on-prep/)
115 [trial-to-prevent-stis-in-msm-on-prep/](https://www.croiconference.org/abstract/anrs-174-doxyvac-an-open-label-randomized-trial-to-prevent-stis-in-msm-on-prep/)
- 116 3. California Department of Public Health. Doxycycline Post-Exposure Prophylaxis (doxy-PEP)
117 for the Prevention of Bacterial Sexually Transmitted Infections (STIs). State of California
118 Health and Human Services Agency. 2023 Apr 28;
- 119 4. San Francisco Department of Public Health. Health Update: Doxycycline Post-Exposure
120 Prophylaxis Reduces Incidence of Sexually Transmitted Infections. SFDPH Population Health
121 Division. 2022 Oct 20;
- 122 5. Mortimer TD, Grad YH. A Genomic Perspective on the Near-term Impact of Doxycycline Post-
123 exposure Prophylaxis on *Neisseria gonorrhoeae* Antimicrobial Resistance. *Clin Infect Dis.*
124 2023 May 4;ciad279.
- 125 6. Whiley DM, Tickner JA, Kundu RL, Hogan TR, Hal SJ van, Lahra MM. Selection of *Neisseria*
126 *gonorrhoeae* ceftriaxone resistance using doxycycline post-exposure prophylaxis. *Lancet*
127 *Infect Dis.* 2023 Aug 1;23(8):e268–9.
- 128 7. Kong FYS, Kenyon C, Unemo M. Important considerations regarding the widespread use of
129 doxycycline chemoprophylaxis against sexually transmitted infections. *J Antimicrob*
130 *Chemother.* 2023 Jul 1;78(7):1561–8.
- 131 8. Truong R, Tang V, Grennan T, Tan DHS. A systematic review of the impacts of oral
132 tetracycline class antibiotics on antimicrobial resistance in normal human flora. *JAC-*
133 *Antimicrob Resist.* 2022 Feb 1;4(1):dlac009.
- 134 9. Traeger MW, Mayer KH, Krakower DS, Gitin S, Jenness SM, Marcus JL. Potential impact of
135 doxycycline post-exposure prophylaxis prescribing strategies on incidence of bacterial
136 sexually transmitted infections. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2023 Aug
137 18;ciad488.
- 138 10. Reichert E, Grad YH. Resistance and prevalence implications of doxycycline post-exposure
139 prophylaxis for gonorrhea prevention in men who have sex with men: a modeling study
140 [Internet]. medRxiv; 2023 [cited 2023 Sep 8]. p. 2023.04.24.23289033. Available from:
141 <https://www.medrxiv.org/content/10.1101/2023.04.24.23289033v1>